// App-Quantinova.ai

e15053 : Retronectin and anti-CD3 monoclonal antibody actived T cell combined anti-PD-1 therapy in heavy-treated renal cell cancer.

Researchers

Presenter

  • Ling-Di Zhao

Principal Investigators

  • Tiepeng Li

  • Wei Li

  • Yonghao Yang

  • Quanli Gao

Medical Centers

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Cancer Hospital affiliated to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

  • Cancer Hospital affiliated to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

  • Cancer Hospital affiliated to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • RetroNectin

  • Nivolumab

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved